Aptiv Solutions has grabbed a key piece to the tech puzzle it has been assembling to provide drug and device developers with adaptive clinical trials. The Reston, VA-based CRO, which launched last year through a series of mergers, has inked a partnership deal with software and services provider Tessella to gain access to an application for designing early-stage trials. In an interview with FierceBiotech IT, Aptiv CEO and Chairman Pat Donnelly explained how his company grew from an idea to become the top provider of complex adaptive trials services with a pot of $70 million in venture money raised in 2008. "We found that there really was no true service provider that understood the nuances of adaptive trials, the requirements that the regulatory agencies needed, and also some of the software," Donnelly said. Article